GHRS vs LBRX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
GHRS · GH Research$17.53 ▼ 5.55%
LBRX · LB Pharmaceuticals$38.85 ▼ 2.97%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- GHRS +20.2%
- LBRX +140.7%
Head to head
| Metric | GHRS | LBRX |
|---|---|---|
| Price | $17.53 | $38.85 |
| Change today | ▼ 5.55% | ▼ 2.97% |
| Market cap | $1.20B | $1.26B |
| Return, 3 months | -37.6% | -19.4% |
| Return, year to date | +38.0% | +74.5% |
| Return, 1 year | +25.1% | +153.4% |
| P/E (TTM) | – | 38.3 |
| P/B | 3.4 | 3.0 |
| P/E percentile vs own 5y | 53rd | 99th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | – |
| Net profit growth (YoY) | -63.1% | -1,561.0% |
| Gross margin | – | – |
| Operating margin | – | – |
| Net margin | – | – |
| Return on equity | -18.8% | -38.8% |
| Analyst target vs. price | +187.1% | +69.6% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 36 | 44 |
| 30-day volatility | 55.2% | 63.5% |
| Max drawdown, 1 year | -42.8% | -31.3% |
| Trend read | Strong downtrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- LBRX is the largest of the group by market value.
- LBRX has returned the most over the past year.
- GHRS has been the calmest stock over the last 30 days.